Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Amortizatization of Intangibles (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Amortizatization of Intangibles for 4 consecutive years, with $440000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 76.68% to $440000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 million, a 60.11% decrease, with the full-year FY2025 number at $3.7 million, down 60.11% from a year prior.
  • Amortizatization of Intangibles was $440000.0 for Q4 2025 at Lexicon Pharmaceuticals, down from $732000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $3.3 million in Q2 2024 to a low of $440000.0 in Q4 2025.
  • A 3-year average of $1.7 million and a median of $1.4 million in 2024 define the central range for Amortizatization of Intangibles.
  • Biggest YoY gain for Amortizatization of Intangibles was 5.22% in 2025; the steepest drop was 76.68% in 2025.
  • Lexicon Pharmaceuticals' Amortizatization of Intangibles stood at $2.0 million in 2023, then decreased by 5.84% to $1.9 million in 2024, then tumbled by 76.68% to $440000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Amortizatization of Intangibles are $440000.0 (Q4 2025), $732000.0 (Q3 2025), and $1.2 million (Q2 2025).